XNAS · Laboratory Analytical Instruments · S&P 500
$74.61
-$0.71 (-0.94%) today
Open $75.32 High $78.10 Low $74.13 Vol 212K Avg $75.31
Find similar stocks by technical condition — S&P 500 universe
| Symbol | Company Name | Exchange | Currency | Category |
|---|---|---|---|---|
| NEWP | New Pacific Metals Corp. | XASE | USD | - |
| IAG | IAMGold Corporation | XNYS | USD | - |
| BHST | BioHarvest Sciences Inc. Common Stock | XNAS | USD | - |
| BLDP | Ballard Power Systems Inc. | XNAS | USD | - |
| VFS | VinFast Auto Ltd. Ordinary Shares | XNAS | USD | - |
| CHY | Calamos Convertible and High Income Fund | XNAS | USD | - |
| AEC | Anfield Energy Inc. Common Shares | XNAS | USD | - |
| GCDT | Green Circle Decarbonize Technology Limited | XASE | USD | - |
| OXLC | Oxford Lane Capital Corp. | XNAS | USD | - |
| DTSS | Datasea Intelligent Technology Ltd. Class A Ordinary Shares | XNAS | USD | - |
52-week price range
Price is 0.0% above its 52-week low and 0.0% below its 52-week high. Trading in the lower half of its annual range — closer to the floor than the ceiling.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.